XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

BACKGROUND: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, the development of alternative synthetic lethality s...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Reem, Alblihy, Adel, Toss, Michael S., Algethami, Mashael, Al Sunni, Rabab, Green, Andrew R., Rakha, Emad A., Madhusudan, Srinivasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758562/
https://www.ncbi.nlm.nih.gov/pubmed/33425022
http://dx.doi.org/10.1177/1758835920974201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758562/
https://www.ncbi.nlm.nih.gov/pubmed/33425022
http://dx.doi.org/10.1177/1758835920974201

Ejemplares similares